Fate of ¹⁷⁷Lu-CHX-A"-DTPA-rituximab in vitro evaluation in Raji cell line

Radioimmunotherapy is an emerging treatment modality for various types of cancers. While immunotherapy using monoclonal antibodies has shown promising results, particularly in hematological malignancies, a significant number of patients develop resistance to the treatment, which may be overcome using monoclonal antibodies labeled with suitable therapeutic radioisotopes. In this study, in vitro evaluation studies of ¹⁷⁷Lu-CHX-A^-DTPA-rituximab were performed in Raji cells that overexpress CD20. The extent of internalization of ¹⁷⁷Lu-CHX-A"-DTPA rituximab inside the target cell as well as the impact of cellular toxicity in Raji cells was studied. Thus, the results show a potential of ¹⁷⁷Lu-rituximab as a promising radiopharmaceutical against non-Hodgkin's lymphoma